CVE-2015-3965 describes a high-severity vulnerability affecting Hospira Symbiq Infusion Systems version 3.13 and earlier. This flaw allows remote authenticated attackers with elevated privileges to trigger unanticipated operations by exploiting an incorrectly exposed function. With a CVSS score of 8.8, the vulnerability presents a significant risk, enabling full compromise of confidentiality, integrity, and availability with low attack complexity. There is no evidence of active exploitation, publicly available exploit code, or significant community discussion surrounding this CVE.
| Vendor | Product | Version(s) | CPE |
|---|---|---|---|
<= 3.13CPE matchmatch criteria | cpe:2.3:o:pfizer:symbiq_infusion_system_firmware:*:*:*:*:*:*:*:* |
CVSS version used by this source: 3.0
CVSS:3.0/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
No social media mentions found for this CVE.
The average CVE in this peer group has 0.0 Twitter, 0.0 Reddit, 0.3 Bluesky, 0.1 Mastodon, and 0.2 GitHub mentions.
No media coverage found for this CVE.
The average CVE in this peer group has 0.1 InfoSec Media, 0.0 Vendor Blog, and 0.0 Security Researcher mentions.
Remediation records are not available for this CVE.